April 05, 2012

PLEASANTON, CA– CooperVision, Inc. today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision’s Avaira® Toric two-week silicone hydrogel contact lenses for astigmatism. Avaira® Toric highlights CooperVision’s commitment to provide eye care practitioners with a choice within the two-week modality segment for their patients. CooperVision will re-launch Avaira® Toric with shipments available for select distribution beginning early May 2012.

CooperVision’s Avaira® Toric silicone hydrogel contact lenses offer patients a consistently comfortable lens wearing experience. Avaira® Toric contact lenses also have an optimized ballast design for lens stability providing patients with excellent visual acuity. The consistent fit across the power range offers eye care practitioners a great option for a wide range of astigmatic patients.

Avaira® contact lenses are designed with an innate ability to attract and retain moisture within the lens material without the need for surface treatment or wetting agents. This is thanks to Aquaform® Technology which makes it the only two-week silicone hydrogel toric that is naturally wettable. This technology provides comfort that patients can rely on day after day throughout the entire wearing cycle.

About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges; such as astigmatism, presbyopia, and ocular dryness; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, thereby creating real advantages for customers and wearers.